Infectious disease testing is not one universal blood test. The right choice depends on the suspected organism, exposure date, symptoms, body site, vaccination history, and whether the goal is screening, diagnosing a current infection, confirming a prior infection, or documenting immunity. Antibody tests measure an immune response; antigen tests detect part of an organism; nucleic acid amplification tests (NAATs), including many PCR tests, detect genetic material; cultures grow organisms; and immunity titers assess selected antibodies. A negative result obtained too early or from the wrong specimen site may miss an infection. A positive antibody result may reflect past exposure rather than current disease, so timing, follow-up testing, and clinical context matter.
The assay name tells you what the laboratory is looking for. It does not, by itself, tell you whether the test is appropriate for a specific exposure or symptom. FDA materials distinguish molecular tests, including PCR and other NAATs, from antigen tests that detect organism proteins.1
| Testing method | What it detects | Best use and principal limitation |
|---|---|---|
| Antibody or serology | Your immune response, often reported as IgM, IgG, total antibody, reactive/nonreactive, or a quantitative value | Can support evaluation of prior exposure, immune response, or a stage-specific pattern. Antibodies may not be detectable early, may persist long after an infection resolves, and do not always equal protection. |
| Antigen | A protein or other component of an organism | Can support current-infection detection during an appropriate phase. Sensitivity varies by test, timing, and specimen quality. |
| NAAT | Organism DNA or RNA | Often useful for current infection. The target, specimen type, collection site, and timing still determine whether the result answers the clinical question. |
| PCR | Genetic material amplified through polymerase chain reaction | PCR is a type of NAAT, not a universal test. A PCR result can remain detectable after viable organisms decline in some infections, while a poorly timed or collected specimen can be negative. |
| Culture | Organisms that grow under laboratory conditions | May identify an organism and sometimes support susceptibility testing. Collection quality, transport, organism growth requirements, and recent antimicrobial treatment can affect yield. |
| Immunity titer | A selected antibody associated with prior infection or vaccination | May document laboratory evidence of immunity for certain diseases or programs. It is not a universal measure of protection and may not replace acceptable vaccine records. |
| Result question | What testing may show | What it may not establish alone |
|---|---|---|
| Is genetic material or antigen detectable now? | A properly selected molecular or antigen assay may detect a target in the collected specimen. | Severity, infectiousness, the exact date of acquisition, or infection at an untested body site. |
| Has an immune response developed? | An antibody pattern may support recent infection, past infection, vaccination response, or susceptibility, depending on the organism. | Current active infection, cure, or guaranteed protection without organism-specific guidance. |
| Was the screening result confirmed? | A reflex or confirmatory sequence may resolve a reactive screen using another method. | A complete diagnosis without symptoms, history, examination, and any additional required testing. |
| Does a negative result rule out infection? | A negative result lowers the likelihood of the tested target when timing, specimen, and assay are appropriate. | Infection during a window period, infection at another site, an organism not included in the order, or a poor-quality specimen. |
Instead of asking only, “Which test is most accurate?” ask, “Which target is expected to be detectable in this specimen on this day?” Use the following framework:
For HIV, CDC reports typical detection windows of 10 to 33 days for a NAT, 18 to 45 days for a laboratory antigen/antibody test using blood from a vein, and 23 to 90 days for most antibody tests.3 These ranges are HIV-specific and should not be reused for another infection.
For Lyme disease, antibodies can take several weeks to develop, so an early negative test may not exclude infection. Antibodies can then remain elevated for months to years and should not be used to determine cure.17
Current CDC STI guidance notes that testing may require blood, urine, or swabs from the vagina, throat, or rectum.4 The collection site should reflect anatomy, symptoms, and exposure. Ask whether each exposed site is included before assuming that one specimen provides complete screening.
| Specimen | Common role | Collection and interpretation cautions |
|---|---|---|
| Blood | Antibody, antigen/antibody, titer, IGRA, and selected molecular testing | Timing determines whether the target is detectable. A blood result does not automatically assess genital, rectal, or throat infection. |
| Urine | Selected urogenital NAATs, urinalysis, and urine culture | First-catch and clean-catch collections serve different purposes. Follow the exact order instructions and avoid assuming urine covers every exposure site. |
| Vaginal or cervical swab | Selected STI NAATs and clinician-directed microscopy or culture | Collection method and assay validation matter. Patient-collected vaginal swabs can be appropriate for certain NAATs when instructions are followed.6 |
| Rectal or throat swab | Site-specific gonorrhea or chlamydia testing and other targeted assays | Use a test validated for that site. Urogenital testing alone can miss an extragenital infection.7 |
| Lesion swab | Molecular or culture testing for selected active skin or mucosal infections | When a fresh lesion is present, direct testing may answer a different question from blood antibody testing. |
| Respiratory swab or sputum | Targeted respiratory molecular, antigen, or culture testing | The optimal sample depends on the organism, illness phase, test, and collection technique. |
| Tier | When it fits | How to choose |
|---|---|---|
| Tier 1: Routine or guideline-based screening | Age-, pregnancy-, anatomy-, or risk-based screening recommended by current guidance | Use the applicable national guideline and include relevant specimen sites. |
| Tier 2: Exposure- or symptom-directed testing | A specific exposure, symptom pattern, travel history, outbreak, occupational requirement, or pregnancy concern | Match the organism, method, body site, and timing. Coordinate urgent or complex cases with a clinician. |
| Tier 3: Confirmatory, staging, or monitoring | A reactive screen, established diagnosis, treatment follow-up, or discordant results | Use the organism-specific algorithm. Do not substitute a screening panel for required confirmatory testing. |
STI screening is individualized. Current CDC recommendations vary by age, anatomy, pregnancy, sexual practices, symptoms, exposure site, and risk.5 A broad blood panel cannot replace site-specific swabs or urine testing when those specimens are needed.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Chlamydia and Gonorrhea Test | Supports detection of the named organisms using a molecular method for an appropriate specimen. NAAT is preferred for urogenital chlamydia and gonorrhea testing.67 | Confirm the offered specimen type and whether throat or rectal testing is separately needed. Follow collection instructions exactly. |
| HIV-1/2 Antigen and Antibodies, Fourth Generation | A medically important laboratory antigen/antibody screen for HIV. A reactive screen requires the current diagnostic sequence; an early negative result may require repeat or NAT testing. | No exact standalone Ulta product page was confirmed on August 7, 2026, so this test remains intentionally unlinked in this draft. Use the CDC window periods and seek immediate care after a recent high-risk exposure. |
| RPR Test with Reflex to Titer and Confirmatory Testing | Uses a nontreponemal screen with reflex testing. Syphilis diagnosis requires both a nontreponemal and a treponemal test; either type alone is insufficient.89 | Very early infection, prior treatment, pregnancy, autoimmune conditions, and other factors can affect interpretation. Urgent clinician evaluation is needed for neurologic, ocular, or pregnancy concerns. |
| RPR Monitor with Reflex to Titer | Supports titer monitoring after an established syphilis diagnosis and treatment plan. | It is not the complete initial diagnostic sequence and should be ordered in the context of prior results and a follow-up plan. |
| Herpes Simplex Virus 1 and 2 IgG Antibody HerpeSelect Test with Reflex to HSV-2 Inhibition | Type-specific IgG testing can support selected evaluations when lesions are absent or direct testing was not performed. | CDC does not recommend general-population blood screening for genital herpes. Early results can be negative, false positives occur, and a swab from a fresh lesion is preferred when lesions are present.10 |
| Sexual Health and STI Screening Essential Lab Panel | A convenience panel that may group several screening targets. | Confirm the current components before ordering. A panel name does not guarantee HIV coverage, every STI, or every exposed body site. |
| STD Comprehensive Panel | A broader convenience option for selected screening goals. | “Comprehensive” does not mean universal. Check components, specimen sites, timing, exclusions, and reflex steps against the actual exposure. |
For current education and available categories, review Ulta sexual health and STI testing and the Ulta HIV testing guide. These are education or category pages, not substitutes for an exact product link.
Hepatitis A, B, and C use different markers and algorithms. CDC recommends HBV screening with a triple panel consisting of HBsAg, anti-HBs, and total anti-HBc for adults who have not previously completed screening.1112 For HCV, current-infection testing begins with an antibody screen followed by NAT for HCV RNA when the antibody is reactive.13
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Hepatitis A Antibody, Total | Can show antibodies associated with prior infection or vaccination. It is not the same question as testing for acute hepatitis A. | Interpret with vaccination history, symptoms, and any acute-infection testing. A positive total antibody result does not by itself diagnose current illness. |
| Hepatitis A IgM Antibody | Supports evaluation of suspected recent or acute hepatitis A in the correct clinical setting. | Do not use as a routine immunity screen. Interpret with symptoms, liver tests, exposure history, and clinician guidance. |
| Hepatitis B Surface Antigen Test with Reflex to Confirmation | HBsAg is one marker used to identify current HBV infection and is part of the triple-panel framework. | A single marker cannot distinguish every HBV state. Interpret with total anti-HBc, anti-HBs, prior results, vaccination history, and clinical context. |
| Hepatitis B Surface Antibody, Quantitative | Measures anti-HBs and may support immunity assessment in a defined post-vaccination or clinical context. | Timing matters. A threshold used after a completed vaccine series does not answer whether prior infection occurred; total anti-HBc helps distinguish that history. |
| Hepatitis B Core Antibody, Total | Indicates prior or ongoing exposure to HBV and helps separate vaccine-only immunity from infection-related patterns. | It is not produced by hepatitis B vaccination. An isolated positive result has several possible explanations and requires the full pattern and follow-up. |
| Hepatitis B Titer Test Panel | A panel option for an HBV serology goal. | Confirm the live product components before ordering and compare them with the CDC triple-panel markers or the institution's exact requirement. |
| Hepatitis C Antibody Test with Reflex to RNA Quantitative PCR | Begins with an HCV antibody screen and, when reactive, uses HCV RNA testing to determine whether virus is currently detected. This one-visit reflex sequence follows current CDC operational guidance.1415 | HCV antibodies can remain after spontaneous clearance or successful treatment. A reactive antibody without RNA does not establish current infection. |
| Acute Hepatitis Panel with Reflex to Confirmation | A broader option when acute viral hepatitis is being evaluated. | Confirm current components and reflex rules. Acute symptoms, jaundice, severe abdominal pain, confusion, bleeding, or dehydration require clinician evaluation. |
| Hepatitis Panel, General | A multi-marker option for selected hepatitis questions. | Review the exact components. A broad panel may omit the marker or follow-up test needed for a specific screening, immunity, or current-infection goal. |
Hepatitis infections can also affect liver chemistry and function. For broader context, see Liver Function Tests.
An immunity titer may help when vaccine records are unavailable or an employer, school, clinical program, or clinician requires laboratory evidence. It should not be described as a universal “immunity score.” ARUP Consult notes that laboratory testing can provide evidence of immunity but cannot definitively establish protection in every circumstance; routine serology is not always indicated when acceptable documentation exists.24
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| MMR Titer Test | Assesses selected measles, mumps, and rubella IgG antibodies for a documentation or clinical question. | Measles IgG and rubella IgG can support immunity assessment, but mumps IgG does not necessarily predict neutralizing antibody or protection.212223 |
| Varicella Titer Test | Assesses VZV IgG associated with prior infection or vaccination for selected documentation needs. | Commercial IgG assays can miss vaccine-induced immunity. For suspected active chickenpox or shingles, lesion PCR is preferred; an immunity titer answers a different question.20 |
| Tetanus and Diphtheria Titer Test | Measures selected antibodies for a special clinical or administrative question. | Do not use routine titers to replace current vaccination recommendations unless a qualified clinician or receiving institution directs testing. |
| Student Titers Panel | A convenience panel for school or clinical-program documentation. | Obtain the institution's written list first. Confirm current product components, accepted methods, thresholds, and whether vaccine records are preferred. |
| Immunity Panel Plus | A broader convenience panel for selected documentation goals. | Confirm every included test against the actual requirement. Extra tests can create confusing results without improving documentation. |
| Vaccination Status Test Panel - Basic | A multi-antibody option for selected vaccination-status questions. | Confirm live components and acceptance criteria. A panel result does not guarantee clinical protection or replace an indicated vaccine dose. |
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| QuantiFERON-TB Gold Plus Tuberculosis Test | An interferon-gamma release assay that measures the immune response to TB proteins in whole blood.16 | A positive result indicates TB infection but does not distinguish inactive TB infection from TB disease. Symptoms or a positive result require medical evaluation. |
| Lyme Disease Antibody Test with Reflex to Blot (IgG, IgM) | Uses an antibody-based two-step approach for a compatible exposure and clinical presentation. | Testing can be falsely negative early. Positive antibodies can persist for years and do not prove that current symptoms are caused by active Lyme disease.17 |
| Epstein-Barr Virus Antibody Test Panel | Measures a pattern of EBV antibodies that may help distinguish susceptibility, recent infection, and past infection.18 | Individual antibody results should be interpreted as a pattern. High or persistent IgG values do not by themselves prove that EBV is causing chronic symptoms. |
| Mycoplasma pneumoniae Antibodies (IgG, IgM) | A serologic option that may provide adjunctive evidence in selected evaluations. | CDC identifies NAAT as the preferred method for acute M. pneumoniae diagnosis. Serology should not be presented as the preferred stand-alone acute test.19 |
Some laboratory tests add context without identifying a specific pathogen. Use them to answer a defined secondary question, not as substitutes for organism-specific testing.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Urine Culture Test | Grows organisms from a urine specimen to support UTI diagnosis and organism identification.25 | Use the instructed clean-catch method. Contamination, transport delay, dilute urine, and antibiotics started before collection can affect the result. |
| Urinalysis (UA) Complete | Assesses cells, chemicals, and other urine findings that can support evaluation of urinary symptoms. | It does not identify the organism or replace culture when organism identification and susceptibility information are needed. |
| Complete Blood Count with Differential and Platelets - CBC Test | Measures blood cells and may provide nonspecific context about inflammation, infection, anemia, or platelet abnormalities. | It cannot identify a pathogen, determine the exposure date, or rule a specific infection in or out by itself. |
For a broader explanation of blood-count context, see CBC and Anemia Blood Tests. To compare infection with other inflammatory causes, see Inflammation and Autoimmune Blood Tests.
| Approach | Advantages | Tradeoffs |
|---|---|---|
| One targeted test | Matches a clear organism, marker, or documentation goal and can reduce unrelated findings. | May miss another necessary marker, reflex step, or exposed site if the original question was incomplete. |
| Reflex sequence | Uses the initial result to trigger a defined confirmatory or follow-up test from the same specimen when available. | Reflex rules vary. Confirm what triggers the additional test and whether a new specimen might still be required. |
| Convenience panel | Groups multiple related tests for a defined goal such as STI screening, viral hepatitis evaluation, or immunity documentation. | Can include unnecessary tests or omit a needed body site, target, or confirmatory step. Read the current component list before ordering. |
Preparation varies by order. MedlinePlus advises following the specific instructions supplied for each test and discussing medicines or supplements rather than stopping them on your own.26
“Reactive” often describes a screening signal that may require confirmation. “Detected” usually means the assay found its target in that specimen. “Positive” depends on the method and reporting convention. “Immune” should be used only when the organism-specific test, threshold, timing, and applicable guideline support that interpretation.
A reference interval describes values observed in a laboratory population. A decision threshold is selected for a specific clinical or administrative purpose. Infectious disease assays may instead report detected/not detected, reactive/nonreactive, an index value, a titer, or a multi-marker pattern. Always use the laboratory's report and organism-specific guidance.
Example only: Jordan had a possible exposure 12 days ago and has no symptoms. A screening result is negative. That result does not automatically close the question because the test method, specimen site, and window period are not yet known. Jordan checks the order and learns that it assessed a urogenital specimen but not the throat, even though oral exposure occurred. The clinician recommends site-specific testing and a later repeat based on the organism's detection window. This example shows why “negative” is not a complete interpretation without knowing what was tested, where the specimen came from, and when it was collected.
Post-treatment retesting schedules are infection-specific. CDC provides separate guidance for detecting repeat chlamydia, gonorrhea, trichomoniasis, and syphilis infections after treatment.2
Do not repeat tests indefinitely without a defined question. Some antibodies remain positive for years or life, and repeated measurement may not show cure or ongoing disease.
Seek prompt medical evaluation for trouble breathing, chest pain, confusion, fainting, severe dehydration, stiff neck, a rapidly spreading rash, severe headache, new weakness, eye pain or vision change, jaundice with severe illness, uncontrolled bleeding, severe pelvic or testicular pain, or symptoms during pregnancy. After a recent possible HIV exposure, seek time-sensitive medical advice about post-exposure prophylaxis rather than waiting for a routine test. Suspected meningitis, sepsis, severe pneumonia, active TB disease, neurologic syphilis, or a serious infection in an immunocompromised person requires clinician-directed care.
Ulta Lab Tests provides direct access to many laboratory tests where permitted. Start by browsing infectious disease testing, then match the order to the organism, testing goal, specimen, body site, and timing.
PCR is one type of nucleic acid amplification test. NAAT is the broader category. Always confirm the organism, specimen type, body site, and test target instead of relying on the method label alone.
Not necessarily. Some antibodies indicate past exposure, vaccination, or a stage-specific immune response and may persist long after infection resolves. Current infection may require an antigen, molecular, culture, or multi-marker interpretation.
For selected diseases, a specific IgG or quantitative antibody result may provide laboratory evidence of immunity. The meaning depends on the disease, assay, threshold, timing, vaccination history, and the receiving institution's rules. No single titer is a universal immunity score.
You can sometimes test early, but a negative result may not close the question. The useful date depends on the organism and method. Time-sensitive prevention or treatment should never be delayed while waiting for a later testing window.
No. A urine or urogenital specimen does not automatically assess the throat or rectum. Ask whether each exposed site needs its own validated swab test.
Screening tests are designed to identify results that need a second step. Confirmation may use a different target or method to improve specificity, distinguish current from past infection, or establish the final diagnostic pattern.
A panel groups several tests for convenience; an individual test answers one defined question. Review a panel's current components, specimen sites, window periods, and exclusions before assuming it is complete.
Many infectious disease tests do not require fasting, but another test in the same order might. Follow the current instructions for every ordered item rather than using a general rule.
They can affect some organism-detection and culture results, while antibody responses may behave differently. Tell the clinician and laboratory what you took and when. Do not stop treatment without medical advice.
No. A positive IGRA supports TB infection. A medical evaluation, symptom review, chest imaging, and other testing may be needed to distinguish inactive infection from TB disease.
No. Antibodies can persist for months or years. Interpretation requires compatible exposure, symptoms, timing, the recommended testing algorithm, and consideration of other causes.
Not automatically. Written vaccination records may be the preferred evidence, and some commercial assays can miss vaccine-induced immunity. Ask the receiving institution or clinician what documentation is accepted before ordering.
Good infectious disease testing begins with a precise question. Choose the organism-specific method, collect the correct specimen from the correct body site, account for the exposure window, and plan the required confirmation or repeat testing before interpreting the result. Antibody, antigen, PCR, NAAT, culture, and immunity titer tests each provide different evidence. Their value comes from matching that evidence to symptoms, exposure history, vaccination records, and current guidelines.
Ulta Lab Tests offers laboratory-testing services and links to tests or panels discussed on this page. This educational article is not medical advice, does not diagnose or treat disease, and does not replace a licensed healthcare professional, public-health guidance, prenatal care, or emergency evaluation. Product availability, panel contents, prices, laboratory methods, specimen requirements, and guidelines can change. Recheck them on the day of use.
Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.
Written by: John R. | Originally published: August 1, 2026 | Last updated: August 7, 2026
Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.Update history
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
